Asahi Kasei wins FDA approval for acquired HSV treatment

· Health · Japan · United States

Japanese pharma Asahi Kasei Therapeutics has received FDA approval for a herpes treatment it acquired earlier this year in a deal worth almost $1 billion. The approval, announced late Friday, covers the drug now branded Hovilpri. The clearance marks the first major regulatory milestone for the asset since Asahi Kasei brought it in-house, validating its bet on the antiviral. It also broadens the treatment options in a category where HSV therapies have seen relatively little innovation.

Why it matters：A new approved antiviral expands competition in HSV care and tests whether acquisition-led pipelines can clear regulators quickly.

Key points

  • The FDA approval covers a drug now branded Hovilpri.
  • Asahi Kasei acquired the asset early this year in an almost $1 billion deal.
  • The decision was announced late Friday.

Sources (original reporting)

More stories from this day